Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure
How to buy Nektar Therapeutics stock
Learn how to easily invest in Nektar Therapeutics stock.
Nektar Therapeutics is a biotechnology business based in the US. Nektar Therapeutics shares (NKTR) are listed on the NASDAQ and all prices are listed in US Dollars. Nektar Therapeutics employs 740 staff and has a trailing 12-month revenue of around $96.3 million.
How to buy shares in Nektar Therapeutics
- Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
- Open your brokerage account. Complete an application with your details.
- Confirm your payment details. Fund your account.
- Research the stock. Find the stock by name or ticker symbol – NKTR – and research it before deciding if it's a good investment for you.
- Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
- Check in on your investment. Optimize your portfolio by tracking your stock.
What's in this guide?
Nektar Therapeutics stock price (NASDAQ: NKTR)Use our graph to track the performance of NKTR stocks over time.
Nektar Therapeutics shares at a glance
|Latest market close||$3.14|
|52-week range||$3.02 - $19.37|
|50-day moving average||$4.12|
|200-day moving average||$6.90|
|Wall St. target price||$4.71|
|Dividend yield||$0 (0%)|
|Earnings per share (TTM)||$-2.66|
Buy Nektar Therapeutics shares from these brokeragesCompare special offers, low fees and a wide range of types of investments among top trading platforms.
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
Is it a good time to buy Nektar Therapeutics stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Nektar Therapeutics price performance over time
|1 week (2022-09-16)||-9.51%|
|1 month (2022-08-25)||-33.76%|
|3 months (2022-06-24)||-22.08%|
|6 months (2022-03-25)||-44.13%|
|1 year (2021-09-24)||-83.04%|
|2 years (2020-09-25)||-82.17%|
|3 years (2019-09-25)||18.8|
|5 years (2017-09-25)||22.92|
Is Nektar Therapeutics stock undervalued or overvalued?
Valuing Nektar Therapeutics stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Nektar Therapeutics's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Nektar Therapeutics's PEG ratio
Nektar Therapeutics's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 3.22. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Nektar Therapeutics's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
Nektar Therapeutics financials
|Revenue TTM||$96.3 million|
|Gross profit TTM||$77 million|
|Return on assets TTM||-21.74%|
|Return on equity TTM||-76.97%|
|Market capitalisation||$665.3 million|
TTM: trailing 12 months
Nektar Therapeutics share dividends
We're not expecting Nektar Therapeutics to pay a dividend over the next 12 months.
Have Nektar Therapeutics's shares ever split?
Nektar Therapeutics's shares were split on a 2:1 basis on 22 August 2000. So if you had owned 1 share the day before before the split, the next day you'd have owned 2 shares. This wouldn't directly have changed the overall worth of your Nektar Therapeutics shares – just the quantity. However, indirectly, the new 50% lower share price could have impacted the market appetite for Nektar Therapeutics shares which in turn could have impacted Nektar Therapeutics's share price.
Nektar Therapeutics share price volatility
Over the last 12 months, Nektar Therapeutics's shares have ranged in value from as little as $3.02 up to $19.37. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Nektar Therapeutics's is 1.1526. This would suggest that Nektar Therapeutics's shares are a little bit more volatile than the average for this exchange and represent, relatively-speaking, a slightly higher risk (but potentially also market-beating returns).
Nektar Therapeutics overview
Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in areas of unmet medical need in the United States and internationally. The company's products include Bempegaldesleukin, a CD122-preferential interleukin-2 (IL-2) pathway agonist, which is in phase 3 clinical trial to treat metastatic melanoma, renal cell carcinoma, muscle-invasive bladder cancer, squamous cell carcinoma of the head and neck, and adjuvant melanoma; phase 2 clinical trial for the treatment of renal cell carcinoma, non-small cell lung cancer, and urothelial cancer; phase 1/2A clinical trial to treat squamous cell carcinoma of the head and neck; phase 1/2 clinical trial for the treatment of solid tumors; and phase 1B clinical trial to treat COVID-19. It is also developing NKTR-358, a cytokine Treg stimulant that is in phase 2 clinical trial for the treatment of systemic lupus erythematosus and ulcerative colitis, as well as phase 1B clinical trial to treat atopic dermatitis and psoriasis; NKTR-255, an IL-15 receptor agonist, which is in phase 1/2 clinical trial for the treatment of non-Hodgkin's lymphoma and multiple myeloma, and head and neck cancer and colorectal cancer; and NKTR-262, a toll-like receptor agonist that is in phase 1/2 clinical trial to treat solid tumors, as well as various other drug candidates. The company has collaboration agreements with Takeda Pharmaceutical Company Ltd. ; AstraZeneca AB; UCB Pharma S. A. ; F.
Nektar Therapeutics in the news
Nektar Therapeutics Presents Data for Rezpegaldesleukin (LY3471851) in Patients with Atopic Dermatitis and Psoriasis from Two Separate Clinical Studies at 2022 European Academy of Dermatology (EADV) Congress
Frequently asked questionsWhat percentage of Nektar Therapeutics is owned by insiders or institutions?
Currently 1.115% of Nektar Therapeutics shares are held by insiders and 98.795% by institutions. How many people work for Nektar Therapeutics?
Latest data suggests 740 work at Nektar Therapeutics. When does the fiscal year end for Nektar Therapeutics?
Nektar Therapeutics's fiscal year ends in December. Where is Nektar Therapeutics based?
Nektar Therapeutics's address is: 455 Mission Bay Boulevard South, San Francisco, CA, United States, 94158 What is Nektar Therapeutics's ISIN number?
Nektar Therapeutics's international securities identification number is: US6402681083 What is Nektar Therapeutics's CUSIP number?
Nektar Therapeutics's Committee on Uniform Securities Identification Procedures number is: 457191104
More guides on Finder
What are the FAANG stocks and how do you invest in them?
Looking to invest in tech? Here’s how to buy shares in the major tech companies, known as FAANG stocks.
How to buy soccer stocks
A simple guide to buying stocks in your favorite European soccer team.
How to buy Juventus stock
Steps to owning and managing JUVE, with 24-hour and historical pricing before you buy.
How to buy AS Roma stock
Steps to owning and managing ASR, with 24-hour and historical pricing before you buy.
How to buy Borussia Dortmund stock
Steps to owning and managing BVB, with 24-hour and historical pricing before you buy.
How to buy Lead Real Estate Co. (LRE) stock when it goes public
Everything we know about the Lead Real Estate Co. IPO, plus information on how to buy in.
How to buy Third Harmonic Bio (THRD) stock
Everything we know about the Third Harmonic Bio IPO, plus information on how to buy in.
How to buy LINKBANCORP (LNKB) stock
Everything we know about the LINKBANCORP IPO, plus information on how to buy in.
Here are the stocks that benefit from inflation, as well as industries to keep an eye on to reduce the impacts of inflation on your portfolio.
We’ve rounded up stats on some of the most popular wheat stocks, along with information on how these stocks compare and how to invest.
Ask an Expert